While anti-vascular endothelial growth factor (VEGF) therapy has proved to be of benefit for neovascular or ‘wet’ AMD[3], there are presently no treatments that mitigate progression of photoreceptor loss in the more common atrophic or ‘dry’ form of AMD[4]. Here, VEGFA is linked to age-related macular degeneration.